Syndax Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$9.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $18.77M, a 4.84% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$28.35M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $25.70M, a 120.46% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.10M, a 94.76% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $42.17M, a 120.32% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $19.14M, a 28.73% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $14.87M, a 57.81% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $9.42M, a 240.23% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$9.58M 10-Q · filed 2026-08-04 | $16.12M derived: sum of 3 quarters · filed 2026-08-04 | $17.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$28.35M 10-Q · filed 2026-04-30 | -$2.65M derived: sum of 2 quarters · filed 2026-04-30 | -$1.55M derived: sum of 3 quarters · filed 2026-04-30 | $16.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $25.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.80M derived: sum of 2 quarters · filed 2026-02-26 | $44.70M derived: sum of 3 quarters · filed 2026-08-04 | $42.17M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $19.00M derived: sum of 2 quarters · filed 2026-08-04 | $16.47M 10-Q · filed 2025-11-03 | $28.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $17.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $15.37M 10-Q · filed 2026-08-04 | $27.02M derived: sum of 3 quarters · filed 2026-08-04 | $48.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$2.53M 10-Q · filed 2026-04-30 | $9.12M derived: sum of 2 quarters · filed 2026-04-30 | $30.16M derived: sum of 3 quarters · filed 2026-04-30 | $23.32M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $11.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.69M derived: sum of 2 quarters · filed 2026-02-26 | $25.85M derived: sum of 3 quarters · filed 2026-02-26 | $19.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $21.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $14.19M derived: sum of 2 quarters · filed 2025-11-03 | $7.48M 10-Q · filed 2025-11-03 | $14.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$6.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$13.55M 10-Q · filed 2025-08-04 | -$6.05M derived: sum of 3 quarters · filed 2026-02-26 | $8.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$6.71M 10-Q · filed 2025-05-05 | $794.00K derived: sum of 2 quarters · filed 2026-02-26 | $14.95M derived: sum of 3 quarters · filed 2026-02-26 | $17.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.66M derived: sum of 2 quarters · filed 2026-02-26 | $24.04M derived: sum of 3 quarters · filed 2026-02-26 | $14.87M 10-K · filed 2026-02-26 |
| 2023-09-30 | $14.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $16.54M derived: sum of 2 quarters · filed 2024-11-05 | $7.36M 10-Q · filed 2024-11-05 | $18.33M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$6.80M 10-Q · filed 2024-08-01 | $4.17M derived: sum of 3 quarters · filed 2025-03-03 | $309.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$9.17M 10-Q · filed 2024-05-08 | $1.79M derived: sum of 2 quarters · filed 2025-03-03 | -$2.07M derived: sum of 3 quarters · filed 2025-03-03 | -$3.61M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $10.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $7.11M derived: sum of 2 quarters · filed 2025-03-03 | $5.57M derived: sum of 3 quarters · filed 2025-03-03 | $9.42M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$5.40M derived: sum of 2 quarters · filed 2023-11-02 | -$1.54M 10-Q · filed 2023-11-02 | -$907.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.32M 10-Q · filed 2023-08-03 | $2.95M derived: sum of 3 quarters · filed 2024-02-27 | $4.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.86M 10-Q · filed 2023-05-08 | $4.49M derived: sum of 2 quarters · filed 2024-02-27 | $6.39M derived: sum of 3 quarters · filed 2024-02-27 | $6.58M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $638.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.53M derived: sum of 2 quarters · filed 2024-02-27 | $2.73M derived: sum of 3 quarters · filed 2024-02-27 | $2.77M 10-K · filed 2024-02-27 |
| 2021-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.09M derived: sum of 2 quarters · filed 2022-11-03 | $2.13M 10-Q · filed 2022-11-03 | $3.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $235.00K 10-Q · filed 2022-08-08 | $1.92M derived: sum of 3 quarters · filed 2023-02-28 | $2.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $41.00K 10-Q · filed 2022-05-09 | $1.73M derived: sum of 2 quarters · filed 2023-02-28 | $2.34M derived: sum of 3 quarters · filed 2023-02-28 | $3.12M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.30M derived: sum of 2 quarters · filed 2023-02-28 | $3.08M derived: sum of 3 quarters · filed 2023-02-28 | $567.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $617.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.39M derived: sum of 2 quarters · filed 2021-11-15 | -$1.12M 10-Q · filed 2021-11-15 | -$571.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $776.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.74M 10-Q · filed 2021-08-09 | -$1.19M derived: sum of 3 quarters · filed 2022-03-01 | -$5.07M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$2.51M 10-Q · filed 2021-05-11 | -$1.96M derived: sum of 2 quarters · filed 2022-03-01 | -$5.84M derived: sum of 3 quarters · filed 2022-03-01 | -$1.91M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.33M derived: sum of 2 quarters · filed 2022-03-01 | $606.00K derived: sum of 3 quarters · filed 2022-03-01 | -$3.41M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $58.00K derived: sum of 2 quarters · filed 2020-11-05 | -$3.96M 10-Q · filed 2020-11-05 | -$3.15M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $3.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$78.00K 10-Q · filed 2020-08-06 | $732.00K derived: sum of 3 quarters · filed 2021-03-12 | $445.00K derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | -$4.02M 10-Q · filed 2020-05-07 | -$3.21M derived: sum of 2 quarters · filed 2021-03-12 | -$3.49M derived: sum of 3 quarters · filed 2021-03-12 | -$3.85M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $810.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $523.00K derived: sum of 2 quarters · filed 2021-03-12 | $163.00K derived: sum of 3 quarters · filed 2021-03-12 | $974.00K 10-K · filed 2021-03-12 |
| 2018-09-30 | -$287.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$647.00K derived: sum of 2 quarters · filed 2019-11-07 | $164.00K 10-Q · filed 2019-11-07 | $1.46M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | -$360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $451.00K 10-Q · filed 2019-08-07 | $1.75M derived: sum of 3 quarters · filed 2020-03-05 | $5.63M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $811.00K 10-Q · filed 2019-05-08 | $2.11M derived: sum of 2 quarters · filed 2020-03-05 | $5.99M derived: sum of 3 quarters · filed 2020-03-05 | $6.12M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $5.18M derived: sum of 2 quarters · filed 2020-03-05 | $5.31M derived: sum of 3 quarters · filed 2020-03-05 | $5.30M 10-K · filed 2020-03-05 |
| 2017-09-30 | $3.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $4.01M derived: sum of 2 quarters · filed 2018-11-05 | $4.01M 10-Q · filed 2018-11-05 | $4.97M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $122.00K 10-Q · filed 2018-08-08 | $1.08M derived: sum of 3 quarters · filed 2019-03-07 | $3.26M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$7.00K 10-Q · filed 2018-05-09 | $951.00K derived: sum of 2 quarters · filed 2019-03-07 | $3.13M derived: sum of 3 quarters · filed 2019-03-07 | $3.55M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $958.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $3.13M derived: sum of 2 quarters · filed 2019-03-07 | $3.56M derived: sum of 3 quarters · filed 2019-03-07 | $4.84M 10-K · filed 2019-03-07 |
| 2016-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.60M derived: sum of 2 quarters · filed 2017-11-08 | $3.88M 10-Q · filed 2017-11-08 | $3.17M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $1.71M 10-Q · filed 2017-08-10 | $991.00K derived: sum of 3 quarters · filed 2018-03-08 | $937.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $1.28M 10-Q · filed 2017-05-09 | $569.00K derived: sum of 2 quarters · filed 2018-03-08 | $515.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.47M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$716.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$770.00K derived: sum of 2 quarters · filed 2018-03-08 | $182.00K derived: sum of 3 quarters · filed 2018-03-08 | -$1.94M 10-K · filed 2018-03-08 |
| 2015-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $898.00K derived: sum of 2 quarters · filed 2016-11-14 | -$1.22M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $952.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$1.17M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$2.12M 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $1.21M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |